Insight, analysis & opinion from Joe Paduda

Oct
25

Drug costs in workers comp – initial survey results

I’m part way through the Seventh Annual Survey of Prescription Drug Management in Workers Comp, and have a couple of initial impressions worth sharing.
First, and no surprise, is the increased concern about the growth of narcotic opioid usage in comp. Every respondent save one has specifically mentioned opioid usage as a significant problem, contributor to drug costs, and/or area of focus. Many have, or are about to, implement programs designed specifically to address narcotic opioids, with some taking rather aggressive positions to attack off-label usage.
Second, respondents are more concerned about drug costs this year than last, and believe executives in their companies are also tracking drug costs with more interest.
Third, more and more payers are using more and more sophisticated programs to deal with drug utilization – involving pharmacists in the prior authorization process, providing access to physicians for review of selected high cost cases, getting tighter and more restrictive formularies, and implementing step therapy programs.
Fourth, most respondents believe compound medications are a very significant problem; several have developed or are working on programs to address compound meds.
Details on these and other findings will be provided in the final report; as always respondents get a detailed copy of the report; there will also be a summary report available to the public.
If you are interested in participating in the survey (insurers, TPAs, self-insured employers, and managed care firms), send an email to infoAThealthstrategyassocDOTcom.
And thanks to those folks who’ve agreed to participate this year – your insights and understanding will help all of us get better at managing drug costs.
You can download copies of past reports here.


Oct
22

What’s driving comp medical costs

Two things – facility costs and pharmacy.
We’ll get to pharmacy next week (I’m finishing up the Seventh Annual Survey of Prescription Drug Management in Workers Comp), but for now here’s a couple quick hits on the growing problem in facility expenses.
Today’s WorkCompCentral [sub req] highlights the results of a recent WCRI study examining cost drivers in North Carolina. a study that indicates the “average hospital payment per claim was about $9500 in North Carolina, the highest among all the states examined. The average charge for inpatient procedures was 49% higher than the median.” [emphasis added]
Note this was back in 2007; while WCRI does good work, the nature of their process is such that the results are somewhat dated.
The fee schedule was changed back in mi-2009, lowering the cap on inpatient hospital reimbursement from 77.07% to 75%, a whole 2.07 percentage points and outpatient from 95% to 79%.
If anyone thinks this is going to make any difference at all, they’re not thinking.
Gaming the ‘percentage off charges’ ‘fee schedule’ is ridiculously easy; this nominal decrease will have zero effect on actual payments to hospitals, and thus will do nothing to lower payers’ medical costs in North Carolina, costs which, according to WCRI, wer up 9% in 2007.
The fee schedule reduction was a complete waste of time. That may not endear me to the folks who, I am sure, worked diligently to address the issue, but that’s a fact. What NC should have done was change the methodology from a percentage off charges to something much more certain and fair – a cost-plus based system would have been a good, albeit imperfect, alternative.
We need a reality check.
Workers comp will pay about $31 billion in medical expense this year.
Health care costs will total about $2.7 trillion this year
.
I raise this often-overlooked fact to point out that employers and insurers will not be able to rely on networks to control costs, as work comp networks have little buying power, and thus little ability to influence price per service.
Therefore, regulators have to step into the breach, and provide real, actionable, metric-based fee schedules based on something much more solid than the facility’s charges.
What does this mean for you?
Higher facility costs will drive medical expense which will drive up combined ratios – and premiums.


Oct
21

Workers comp – deals on the horizon

Now that the Mitchell – Ingenix deal is in the open, the rumor mill – and the fact mill as well – is rife with discussion of pending acquisitions, investments, and mergers in the work comp managed care business.
Tops on the list is the pending Intracorp – Genex deal. This has been in the works for some time (fingers crossed, as I predicted CIGNA would sell IntraCorp months ago and I’m running out of time), but word is things are still progressing. That’s not to say it couldn’t fall apart, but at this point that doesn’t look likely. Genex, owned by a private equity firm, would certainly benefit from the additional scale added by an acquisition of competitor Intracorp. And now that forme CIGNA Chairman Ed Hanway is retired, there’s no one in the executive suite at the big healthplan preventing a deal.
Here’s hoping this one gets resolved soon; this has been dragging on so long it has to be exhausting for all parties.
Specialty managed care firm Universal SmartComp was on the block as well, with sources indicating there were two fairly serious potential buyers – one strategic and the other financial. Evidently things are at a standstill after one potential investor went deep into the due diligence process. This is always a tricky part of the deal, as the seller’s optimistic forecasts and desire for a high multiple come up against the potential buyer’s motivation to buy the property at a price that will make for big profits at sale.
While they may not be announced before the National Work Comp and Disability Conference, there are a couple of others in process, one a ‘platform’ type deal and the other an addition to a current business. These are a bit more iffy, but with the tax laws turning them into pumpkins at the end of the year (which is looking increasingly likely), owners may be anxious to get them done.
And that’s just what I know; I’m sure there are others out there yet to hit my radar.
Which brings up the question – why?
No clear answer, except work comp services is still very much a techno-phobic, mom-and-pop, decentralized industry,
one that smart financial and strategic buyers believe will generate big profits through consolidation.
Perhaps.
It is also a hidebound, relationship-based and relationship-driven industry, a model that doesn’t ‘scale’ well, if at all. It is highly affected by regulatory risk, and subject to external influences beyond the ken of most in the industry, let alone outsiders evaluating a business model.
So yes, there are big opportunities. There are also big risks.


Oct
20

The Mitchell – Ingenix deal – details and history

The official announcement was released a bit ago, and there aren’t many more details than we shared yesterday.
I would note that there are several allusions to the new entity being the ‘market share leader‘; in a subsequent conversation with Nina Smith-Garmon, senior vice president and general manager of the bill review business, she opined that Mitchell will be the market leader with “thirty percent plus” share after the deal closes in thirty days.
This may well be the case, although my sense is Coventry is not far behind – and may be about the same in terms of bill volume. That, and Medata is coming up fast after adding PMA, TriStar, Healthcare Solutions (Procura, not Indiana), and BerkshireHathaway HomeState to their client roster – and more than a couple of ex-FairIsaac staffers as well over the last twelve months.
Paul Glover et al are pushing hard with Stratacare; their acquisition of Bunch will likely lead to at least one current Ingenix customer switching to their platform.
Just before I was about to post this, I got a call from Nina Smith-Garmon, of SmartAdviser, who mentioned several times the strategic aspects of the deal. Here are the top takeaways.
1. Mitchell will attempt to convert all current PowerTrak customers to SmartAdviser.
2. Ingenix’ new IMBR platform is history; neither Ingenix nor Mitchell will continue development of IMBR.
3. Mitchell bought the First Notice business as well as the bill review business; contrary to earlier speculation (mine and others’) the state fee schedule development business did not change hands.
4. Most of the PowerTrak employees will ‘come over’ to Mitchell, Smith-Garmon said only a handful will not make the transition. (no indication on whether they’ll end up back at UHG or on the street)
Ms Smith-Garmon’s comments notwithstanding, I don’t know exactly why Mitchell made the acquisition (beyond the press release), but can make a pretty educated guess. And yes, it has to do with top line growth, adding share, and the strategic importance of the business. But at a more granular level, it really comes down to the struggle for new business.
First, a little history. Mitchell Medical has long been the dominant player in the auto claims IT systems business. Back in April of 2008, they bought FairIsaac’s bill review business, a deal that pushed Mitchell into the work comp business (FI also has technology for the auto claims industry).
FairIsaac had purchased the bill review business unit some years before from HNC (formerly CompReview). Mitchell’s current workcomp bill review application, SmartAdvisor (SA) is the latest version of the ‘old’ HNC platform, which in turn was based on the ‘older’ CompReview technology, acquired by HNC in 1999. SA’s rules engine, Capstone, is reputed to be pretty user-friendly in that it can be manipulated and ‘programmed’ at the business analyst level. This capability enables clients to modify rules instead of relying on programmers at the vendor, speeding up the process and possibly reducing cost as well.
Mitchell has had some modest success in growing the business, but of late has not been able to win its ‘fair share’ of deals. The only publicly-announced sale this year was a deal with Rhode Island’s Beacon Mutual in April; Smith-Garmon also noted Mitchell also closed American Family.
Companies have to grow organically (by selling more services to new and existing customers) or through acquisition (buying competitors that come with a ready list of existing revenue-generating customers). If sales aren’t coming, and you want to hold onto that sector, then you’ve got to buy a competitor.
It’s a smart move, as it not only generates instant revenue, but it also eliminates a competitor.
What does this mean for you?
Fewer bill review IT providers is actually a good thing. There isn’t enough revenue to go around, at least not if you want to develop and refine a solid, comprehensive, well-designed and stable application. This will help Mitchell, and Mitchell’s competitors as well.


Oct
19

Mitchell to buy Ingenix’ bill review business

Tomorrow morning Mitchell Medical will announce it has acquired the Ingenix medical bill bill review systems business from United HealthGroup. The deal, which has been tightly held, may also include the assets employed in developing state workers comp fee schedules, although that was not clear as of this afternoon.
This marks yet another step in the consolidation of an industry long in need of just such a change.
When the deal is completed, there will be four dominant firms in workers comp bill review; Coventry, Mitchell, Medata and Stratacare. MCMC also provides bill review services but is not an IT vendor.
Ingenix has been challenged of late as it is in the midst of transitioning their customers from the PowerTrak application to IMBR, a switch that reportedly requires quite a bit of effort and resource on the part of current clients. This has led some current users to test the market and look at other vendors, as they might as well see what’s out there if they have to go through the hassle of conversion regardless.
No word on who, or what, or where, or how many, and I wouldn’t expect much tomorrow.
Stay tuned…


Oct
19

The Blue Cross of Michigan suit – yes, it affects you

Yesterday the NYTimes reported the Justice Department is suing Blue Cross Blue Shield of Michigan for allegedly violating antitrust laws. BCBSMI is accused of requiring hospitals to give BCBSMI ‘most favored nation’ pricing, thereby increasing the prices paid by other health plans and stifling competition.
According to the Times, the Blues contracts had “clauses stipulating that no insurance companies could obtain better rates from the providers than Blue Cross. Some of these contract provisions, known as “most favored nation” clauses, require hospitals to charge other insurers a specified percentage more than they charge Blue Cross — in some cases, 30 to 40 percent more, the lawsuit said.”
Christine Varney, the head of the antitrust division in the Justice Department, said “Our lawsuit alleges that the intent and effect of Blue Cross Blue Shield of Michigan’s contracts is to raise hospital costs for competing health plans…”
The lawsuit also claims that Blue Cross agreed to pay higher prices to certain hospitals to get them to agree to the “most favored nation” clauses.
There are three issues here that deserve your attention.
First, there is no ‘free market’ in health insurance. Most markets are dominated by a single, or at most two, health plans. This is clearly an effort by the Feds to make a statement, to force big health plans and their co-operating health systems and hospital groups to back off and ‘let’ smaller insurers into the market. No one, least of all big insurance companies, likes to be sued by the Federal government, and this very public case has undoubtedly started many health plan legal departments scrambling to prepare briefs for their CEOs detailing their potential liability for the same ‘offenses’.
As a corollary, smaller health plans cannot compete with the big boys because they don’t have the medical dollars required for bargaining purposes. Why would St Tony’s Hospital give a big discount to Mom and Pop’s Health Plan? The answer is simple – they wouldn’t, because they don’t have to – Mom and Pop don’t have any patient dollars that they would (potentially) move to another hospital, so there’s no reason for St Tony to do a deal.
(This basic fact is lost on those politicians and pundits who think that selling health insurance across state lines is a panacea. Health plans’ costs are primarily, and overwhelmingly, determined by the medical costs in the areas they operate – and legalizing cross-border sales of insurance will do nothing to reduce premiums or improve access)
The suit is apparently an effort by the Feds to address this reality, and may well be part of a larger strategy to improve competition ahead of implementing health reform.
Second, many health plans and insurers have most favored nation clauses in their contracts – workers comp payers too. This suit may – and most certainly should – encourage those payers to reconsider the purpose of and risk in those clauses.
I hasten to add that the accusations against BCBSMI go beyond simple MFN clauses; according to the Times, “the Justice Department said that Blue Cross required two hospitals in Saginaw, Mich., to charge most other insurers at least 39 percent more than the hospitals charged Blue Cross. Likewise, it said, in the Detroit area, the contract required three hospitals to “charge Blue Cross’s significant competitors at least 25 percent more than they charge Blue Cross.”
Finally, this highlights the symbiotic payer – provider relationship that is the fabric of our current health system – dominant health plans and dominant health systems working very closely together. If we as a society decide this isn’t the health system we want, than we’re going to have to get very litigious for a very long time. It has taken a century for the system to evolve to this point, and will take decades for any material change. In some instances this works very, very well – think Geisinger, Mayo, Marshfield.
In others, it may well ‘stifle competition’ But lets get serious – how effectively could a newcomer, or even a second tier health plan, really compete without the huge dollars necessary for investments in IT; care management; provider contracting, analysis, and relations; marketing and brand development; and distribution?
It couldn’t, and it can’t.
Like it or not, competing in health insurance, as in many industries, puts a premium on size and scale.
What does this mean for you?
We can already see this, as smaller health plans are being snapped up by bigger competitors, their management all-too-clearly reading the writing on the wall that survival in the post-reform world will require size, and scale, and money far beyond the grasp of most smaller health plans.
Note – A subsidiary of BCBSMI is a consulting client of HSA. While I have no knowledge that in any way pertains to this action, I do know that as an organization BCBSMI is quite sensitive to and cautious about any actions that might be construed to harm competition or interfere in provider practice.


Oct
18

When amateurs run comp insurers

What happens when uniquely unqualified people run workers comp insurers?
Nothing good.
Exhibit One, the disaster in North Dakota, as their IT systems overhaul is now well over budget, behind schedule, and so obviously mismanaged that there’s no date certain when the much-needed and long-delayed conversion will be completed.
After former Director Sandy Blunt was forced out on trumped-up charges, a former State Trooper with zero experience in workers comp was named Director. While Bryan Klipfel may (or may not) be a decent guy, his complete ignorance of anything comp-related didn’t seem to phase the politicians who appointed him to oversee the state agency. And Klipfel didn’t think it was going to be that difficult, saying:
“I’m going to work with Bruce (Furness) [former interim Director] for a couple of weeks, and I’ll just have to learn some of that information as time goes on,” Klipfel said. “My strong points are that I have leadership ability, and I understand human resources, how to deal with people. And I think that’s the big part (of the job) right now.”
As I said a year-and-a-half ago, “He’s going to learn on the job? While getting mentoring for a ‘couple of weeks”? In a business that is incredibly complex? At a time when investments and reserving practices are critically important?
And his qualifications are his understanding of human resources and leadership ability?”
Now we have solid evidence of just how much damage the North Dakota witch hunt has done. Not only has it destroyed the life of one of the finest people I’ve ever had the honor of meeting (Sandy Blunt), it is costing NoDak’s taxpayers and employers millions due to the incompetence of the new Director. And that’s just what’s hit the press.
Specifically, the delay is now projected at two plus years, with cost overruns – so far – at $3.6 million. The Legislature has to approve the funds, leading some to ask ‘what happens if they don’t.
According to the article, “WSI CEO Bryan Klipfel said they were going to remain positive as many contracts are signed under such circumstances.
“We need the system,” Klipfel said. “If we don’t get the money… well, hopefully that doesn’t happen.”
Now THAT’s a forward-thinking CEO, one with enough experience to always have a Plan B – just in case.
There are a lot of good folks at North Dakota’s work comp fund; unfortunately they are being led by a guy who is in way over his head.


Oct
15

A frame of reference – work comp and the rest of the world

Those of us who spend a good deal of time buried in the world of work comp sometimes need to look up and out, to see where we ‘fit’ in the larger world. There’s so much to do, and so few resources to do it, and even less time, that it’s far too easy to keep the head down and just keep plowing forward.
While that’s understandable, it is also a problem – in some cases, a big problem.
Understand that workers’ comp is just the fourth largest line of property and casualty insurance, with just about 10% of total premiums flowing to comp. New capital can flow into, and out of, insurance lines pretty readily. If and when a major catastrophic event hits, comp will be quickly, and dramatically, affected with premiums headed up and capacity down.
Work comp will spend about $31 billion this year on medical expense; the national health care budget is about $2.4 trillion. Comp is less than 1.5% of total medical cost.
Pharmacy expense in comp is about $4.5 billion, that’s about two percent of total pharma costs in the US.
When one considers there will be another thirty million (30,000,000) Americans covered by group health and Medicaid programs in just over three years, at an average cost of about $7500, the relative significance of comp on the national medical scene becomes even more apparent.

What does this mean?
Comp is the flea on the tail of the dog. We can’t tell the dog where to go, or whether to be happy or run or jump, but we sure better be ready for any of its moves.


Oct
13

Are you paying for defective surgical implants?

The answer is probably YES.
When surgical implants are defective or implanted incorrectly, the patient has to go back in for more surgery. And the Work Comp insurer or healthplan or self-insured employer or reinsurer has to pay. The only way to mitigate risk is to track the model and manufacturer for each implant – yes, it’s work, and yes, it’s work worth doing internally or at the very least outsource it to a specialist firm.
How many dollars are we talking here?
Well, joint replacement devices are a $12 billion industry.
spinal_implants_L.gif
(image from www.algor.com/news_pub/cust_app/SMPES/default.asp)
One survey reported that the total world market for spinal implant devices was $4.2 billion; note this study used 2006 data. Another indicated the market was $5 billion in 2005, and predicted growth to $20 billion by 2015. Stryker, one of the major manufacturers, expects growth of 16% per year in the spinal implant market. Yet another report (note opens .pdf) indicated the 2007 worldwide market was $7 billion, with the US accounting for $5.4 billion of that total.
(I’m working on getting more current data and will include it in a follow up piece later this week)
Today’s WSJ reports [link expires 10/15/10] on a new effort by the impant industry to set up a registry for joint replacements:
“manufacturers are backing the “American Joint Replacement Registry” and have chipped in start-up funding.
By joining voluntarily and influencing development, manufacturers may dodge having to face mandated rules down the road. They’ll gain product-durability insight that could help as new, higher-priced devices need to be justified by comparative-effectiveness testing… The nonprofit registry is incorporated in Illinois, which has strong data- protection laws…It also will produce detailed annual reports,”
Couple of notes.
First, this does NOT include spinal and other implants; it is limited to joint replacement implants.
Second, who gets access to the data, and how it is used, is still very much up in the air. Will insurers get to check on a member’s/claimant’s implant if the member requires additional treatment?
So, what to do?
Track those device serial numbers and manufacturers in a secure database. Follow the news to identify recalls and product liability issues and reference your database to identify possible matches.
It’s not easy, and it isn’t foolproof, but its likely to be very cost effective.
For a detailed albeit it somewhat dated discussion of the industry and it’s impact on workers comp, click here.


Oct
11

Selling your company? What NOT to do.

There are several potential deals in process now; for a change there appears to be more sellers than buyers, perhaps due to the pending changes in tax laws. For whatever reason, this is one of those very busy times for private equity firms, their research contractors, and the various people and firms that play some role in the deal assessment process.
I’ve participated in several transactions, and while I don’t pretend to be an expert I have seen enough to know some of the more common mistakes/errors in judgment/exaggerations and the impact of same.
For example.
Don’t claim that any payer that ever sent you a payment is a ‘customer’. Differentiate between real, honest to goodness customers – those you have a long-standing relationship with, and other revenue sources. Sure, you can argue with some basis in fact that anyone who pays you is by definition a customer, but when the smart young research people start digging deeper you’ll find yourself not being able to answer basic questions about this ‘customer’. Which will lead potential Investors to wonder if you know what a customer is and anything about your’s.
Don’t over-enthusiastically forecast. The research firm will vet that info carefully with folks who actually KNOW what’s going on in the market, and you’ll find yourself either a) answering uncomfortable questions or b) answering awkward questions post-deal when you don’t hit your numbers. Or possibly both.
Remember the old adage: pigs get fat and hogs get slaughtered. (hat tip to John Swan) Share the wealth between and among staff; they helped get you there and deserve your thanks. Think of it this way; is another million going to mean as much to you as it would parceled out among your employees?
Do your own due diligence on potential buyers, and absolutely stay away from potential buyers with heavy baggage. There are really good investment firms looking for deals and some on the other end of the spectrum. Ask around, talk to people who’ve sold companies before, and if at all possible who’ve dealt with the firms you’re negotiating with.
Watch the earn-out. It’s perfectly acceptable to have one in the final deal, as long as it’s achievable, provides a nice upside for over-achievement, and the worst case scenario is something you can live with.
Do spend a lot of time with the future board. You are going to have to live with them, and while you don’t have to like them you do have to understand and respect the board.
And finally, be reasonable. A business is just that. It is not a child or even a much-loved black lab.


Joe Paduda is the principal of Health Strategy Associates

SUBSCRIBE BY EMAIL

SEARCH THIS SITE

A national consulting firm specializing in managed care for workers’ compensation, group health and auto, and health care cost containment. We serve insurers, employers and health care providers.

 

DISCLAIMER

© Joe Paduda 2025. We encourage links to any material on this page. Fair use excerpts of material written by Joe Paduda may be used with attribution to Joe Paduda, Managed Care Matters.

Note: Some material on this page may be excerpted from other sources. In such cases, copyright is retained by the respective authors of those sources.

ARCHIVES

Archives